This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Scancell Holdings – Development of vaccine against COVID-19

Scancell Holdings – Development of vaccine against COVID-19

24 Apr 2020

24 April 2020 Scancell Holdings plc (“Scancell” or the “Company”) Scancell to initiate development of novel DNA vaccine against COVID-19 Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that it has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer... Read more

Firms at The Oxford Science Park playing important role in COVID-19 response

Firms at The Oxford Science Park playing important role in COVID-19 response

20 Apr 2020

Firms at The Oxford Science Park playing important role in COVID-19 response From immunology research tools and sequencing to AI and cloud telephony Oxford, UK, April 20 2020 – Several occupiers at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, are involved in the response to the COVID-19 epidemic, including important R&D and clinical support services. Part of the broader crisis response across... Read more

Exscientia – joint initiative to identify COVID-19 drugs with Diamond Light Source & Scripps Research

Exscientia – joint initiative to identify COVID-19 drugs with Diamond Light Source & Scripps Research

31 Mar 2020

Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research   ·       Transatlantic partnership seeks to identify COVID-19 antiviral treatments ·       Exscientia to screen nearly every known approved and investigational drug – 15,000 clinical molecules – against key COVID-19 drug targets to progress rapid... Read more

Lilly and Sitryx Announce Licensing & Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly and Sitryx Announce Licensing & Research Collaboration to Discover & Develop New Immunometabolic Medicines

31 Mar 2020

                                                                                                         Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and... Read more

EVOX THERAPEUTICS AND TAKEDA SIGN MULTI-TARGET RARE DISEASE COLLABORATION

EVOX THERAPEUTICS AND TAKEDA SIGN MULTI-TARGET RARE DISEASE COLLABORATION

26 Mar 2020

Evox Therapeutics Ltd (“Evox” or the “Company”), a leading exosome therapeutics company, is pleased to announce the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited (“Takeda”). The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox’s preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More